2-amino-5-fluoro-4-hydroxy-6-methylpyrimidine | 1597-35-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-amino-5-fluoro-4-hydroxy-6-methylpyrimidine
• 英文别名: 4-hydroxy-2-amino-5-fluoro-6-methylpyrimidine；2-Amino-5-fluoro-4-hydroxy-6-methylpyrimidin；2-Amino-5-fluoro-6-methylpyrimidin-4(1h)-one；2-amino-5-fluoro-4-methyl-1H-pyrimidin-6-one
• CAS: 1597-35-9
• 化学式: C₅H₆FN₃O
• 分子量: 143.121
• InChiKey: CBRFQLVEZWUNEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-5-fluoro-4-hydroxy-6-methylpyrimidine 在 三乙胺 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成 N4-butyl-5-fluoro-6-methylpyrimidine-2,4-diamine
  参考文献：
  名称：

  PYRIMIDINES AND USES THEREOF

  摘要：

  本文提供的各种示例是针对下述公式的化合物的：其中R1-R5在此处被定义，并且这些化合物的用途包括在其他方面抑制受试者的免疫反应。

  公开号：

  US20180215720A1
• 作为产物：
  描述：

  盐酸胍 、 2-氟乙酰乙酸乙酯 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以69%的产率得到2-amino-5-fluoro-4-hydroxy-6-methylpyrimidine
  参考文献：
  名称：

  PYRIMIDINES AND USES THEREOF

  摘要：

  本文提供的各种示例是针对下述公式的化合物的：其中R1-R5在此处被定义，并且这些化合物的用途包括在其他方面抑制受试者的免疫反应。

  公开号：

  US20180215720A1

文献信息

• Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines
  作者：Mallesh Beesu、Alex C. D. Salyer、Kathryn L. Trautman、Justin K. Hill、Sunil A. David

  DOI：10.1021/acs.jmedchem.6b00872

  日期：2016.9.8

  Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the generation of Type 1 helper T cells. A multiplexed high-throughput screen had led to the identification of N-4-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed structure-activity relationship study of this chemotype was undertaken. A butyl substituent at N-4 was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to losses in potency, as did the introduction of aromatic bulk. Drawing from our previous structure-based design, several 5-alkylamino derivatives were evaluated. Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N-4-butyl-6-methylpyrimidine-2,4-diamine. This compound potently induced Th1-biasing IFN-gamma And IL-12 in human blood, but lower levels of the proinflammatory cytokines IL-1 beta, IL-6, and IL-8. These results suggest that the inflammatory and reactogenic propensities of this compound could be considerably more favorable than other TLR8 agonists under evaluation.
• Source regions and timescales for the delivery of water to the Earth
  作者：A. Morbidelli、J. Chambers、J. I. Lunine、J. M. Petit、F. Robert、G. B. Valsecchi、K. E. Cyr

  DOI：10.1111/j.1945-5100.2000.tb01518.x

  日期：2000.11

  Abstract—In the primordial solar system, the most plausible sources of the water accreted by the Earth were in the outer asteroid belt, in the giant planet regions, and in the Kuiper Belt. We investigate the implications on the origin of Earth's water of dynamical models of primordial evolution of solar system bodies and check them with respect to chemical constraints. We find that it is plausible that the Earth accreted water all along its formation, from the early phases when the solar nebula was still present to the late stages of gas‐free sweepup of scattered planetesimals. Asteroids and the comets from the Jupiter‐Saturn region were the first water deliverers, when the Earth was less than half its present mass. The bulk of the water presently on Earth was carried by a few planetary embryos, originally formed in the outer asteroid belt and accreted by the Earth at the final stage of its formation. Finally, a late veneer, accounting for at most 10% of the present water mass, occurred due to comets from the Uranus‐Neptune region and from the Kuiper Belt. The net result of accretion from these several reservoirs is that the water on Earth had essentially the D/H ratio typical of the water condensed in the outer asteroid belt. This is in agreement with the observation that the D/H ratio in the oceans is very close to the mean value of the D/H ratio of the water inclusions in carbonaceous chondrites.
• PYRIMIDINES AND USES THEREOF
  申请人：David Sunil Abraham

  公开号：US20180215720A1

  公开（公告）日：2018-08-02

  The various examples presented herein are directed to compounds of the Formula: wherein R 1 -R 5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.

  本文提供的各种示例是针对下述公式的化合物的：其中R1-R5在此处被定义，并且这些化合物的用途包括在其他方面抑制受试者的免疫反应。